Sironax Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 170

Employees

  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $60.1M

  • Investors
  • 23

Sironax General Information

Description

Manufacturer of novel biopharmaceutical therapeutics designed to treat neurodegenerative, inflammatory, immunological, metabolic, and rare diseases by targeting fundamental pathways of tissue degeneration. The company utilizes target discovery in programmed cell death, medicinal chemistry, translational medicine, and global clinical trial execution, providing healthcare providers, clinical researchers, and patients with small-molecule drug candidates, cell death inhibitors, and targeted anti-inflammatory therapeutics to facilitate disease-modifying treatments across neurodegenerative and inflammatory disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 2, 9th-10th Floor, Number 9, Yike Road
  • Life Science Park, Changping District
  • Beijing, 102206
  • China
+86 010
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Building 2, 9th-10th Floor, Number 9, Yike Road
  • Life Science Park, Changping District
  • Beijing, 102206
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sironax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B1) 13-Sep-2024 $60.1M Completed Clinical Trials - General
3. Early Stage VC (Series B) 02-Aug-2022 Completed Clinical Trials - General
2. Early Stage VC (Series A) 30-Sep-2019 $101M $116M Completed Clinical Trials - General
1. Seed Round 01-Jun-2018 $15M $15M Completed Startup
To view Sironax’s complete valuation and funding history, request access »

Sironax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Manufacturer of novel biopharmaceutical therapeutics designed to treat neurodegenerative, inflammatory, immunological, m
Drug Discovery
Beijing, China
170 As of 2026

New York, NY
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sironax Competitors (3)

One of Sironax’s 3 competitors is Cognition Therapeutics, a Formerly VC-backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cognition Therapeutics Formerly VC-backed New York, NY
Alector Formerly VC-backed South San Francisco, CA
ProMIS Neurosciences Corporation Toronto, Canada
You’re viewing 3 of 3 competitors. Get the full list »

Sironax Patents

Sironax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026137314-A1 Novel antibodies specific for cd98 heavy chain and methods of uses thereof Pending 26-Dec-2024
WO-2026086928-A1 Sarm1 modulators, preparations, and uses thereof Pending 25-Oct-2024
WO-2026001865-A1 Rip1 modulators, preparations, and uses thereof Pending 24-Jun-2024
AU-2025264235-A1 Pde3a/slfn12 disruptors, preparations, and uses thereof Pending 29-Apr-2024
WO-2025228367-A1 Pde3a/slfn12 disruptors, preparations, and uses thereof Pending 29-Apr-2024 A61P35/00
To view Sironax’s complete patent history, request access »

Sironax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sironax Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds
120 Capital Venture Capital Minority
Abu Dhabi Investment Authority Sovereign Wealth Fund Minority
CBC Group (Singapore) PE/Buyout Minority
Future Innovation Fund Corporation Minority
Gaorong Ventures Venture Capital Minority
You’re viewing 5 of 23 investors. Get the full list »

Sironax FAQs

  • When was Sironax founded?

    Sironax was founded in 2017.

  • Where is Sironax headquartered?

    Sironax is headquartered in Beijing, China.

  • What is the size of Sironax?

    Sironax has 170 total employees.

  • What industry is Sironax in?

    Sironax’s primary industry is Drug Discovery.

  • Is Sironax a private or public company?

    Sironax is a Private company.

  • What is Sironax’s current revenue?

    The current revenue for Sironax is .

  • How much funding has Sironax raised over time?

    Sironax has raised $376M.

  • Who are Sironax’s investors?

    120 Capital, Abu Dhabi Investment Authority, CBC Group (Singapore), Future Innovation Fund, and Gaorong Ventures are 5 of 23 investors who have invested in Sironax.

  • Who are Sironax’s competitors?

    Cognition Therapeutics, Alector, and ProMIS Neurosciences are competitors of Sironax.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process